

OHOLO 41st CONFERENCE

News

1997

PROGRESS IN
ALZHEIMER'S AND PARKINSON'S DISEASES

Fourth International Conference

EILAT, ISRAEL, MAY 18 - 23, 1997

ORGANIZERS

Abraham Fisher
Israel Institute for
Biological Research
Ness Ziona, Israel

Mitsuo Yoshida
Jichi Medical School
Tochigi, Japan

Israel Hanin
Loyola University
Chicago
Maywood, Illinois, USA

LOCAL ORGANIZING COMMITTEE

A.D. KORCZYN, Tel Aviv
D. MICHAELSON, Tel Aviv
M. SEGAL, Rehovot
H. SOREQ, Jerusalem

SCIENTIFIC ADVISORY BOARD

Y. AGID, France
D. BOWEN, UK
P. DAVIES, USA
E. GIACOBINI, USA
P. GREENGARD, USA
K. HASEGAWA, Japan
F. HEFTI, USA
I. KANAZAWA, Japan
Z.S. KHACHATURIAN, USA
I.J. KOPIN, USA
T. NAGATSU, Japan
A. NORDBERG, Sweden
E.K. PERRY, UK
P.J. RIEKKINEN, SR., Finland
D.J. SELKOE, USA
L.J. THAL, USA
M.B.H. YOUDIM, Israel

January 22, 1996

Dr. L. Zahn
Council for Tobacco Research
900 3rd Avenue
New York, NY 10022
U.S.A.

Dear Dr. Zahn,

The Fourth International Conference on Alzheimer's and Parkinson's Diseases will take place at the Royal Beach Hotel in Eilat, Israel on May 18-23, 1997. The Conference will focus on clinical and preclinical applications of these disease states, and will feature the most up-to-date basic and clinical developments in this area. This International Conference will highlight discoveries that shed light on potential causes of AD & PD, their pathogenesis and the biological mechanisms that may underline their effective treatment. Main emphasis will be given to all or most AD and PD treatments or therapies approved or under preclinical and clinical development. Special attention will be focused on novel strategies in drug design both for treatment and also for slowing the deterioration/progression of these disease state.

Both senior investigators in the field, as well as newcomers to this sphere of investigation will be involved, and will come from clinics, pharmaceutical, academic, government and private settings from around the world.

Obviously, such a conference could not take place without appropriate funding and necessary financial back-up. We anticipate approximately 800-1000 international and domestic participants at the conference. Hence, we expect the overall expenses should exceed $200,000. We hope to be able to pay the local expenses and travel costs for the key speakers, and to cover publicity, duplication, mailing, plus local costs pertaining to the details of running a 4.5 day conference.

√ *Address Correspondence To:* **Abraham Fisher**, Ph.D., Israel Institute for Biological Research, P.O. Box 19, Ness Ziona 74100
Tel: 972 8 381603/381619, Fax: 972 8 401094

√ *Administrative Secretariat:* P.O. Box 50006, Tel Aviv 61500, Israel
Tel: 972 3 514 0000, Fax: 972 3 514 0077/517 5674
E-MAIL: for Compuserve users: ccmail: ADPD at Kenes, for Internet Users: ADPD @ Kenes.ccmail.compuserve.com

Source: https://www.industrydocuments.ucsf.edu/docs/xxbb0000

The AD/PD Meetings are financed entirely by contributions from non-profit organizations and, most important, from industry. We welcome any financial support that companies like yours can make. Therefore, I am writing to ask for your help in arranging for support from your company to help defray some of the expenses of this conference. We would, of course, be certain to acknowledge this support both in the printed program, and in the conference proceedings as well as the subsequent book.

Your support can be in different ways, for example, in supporting lecturers, workshop, symposia, session within the Conference. We might encourage exhibitions, as well. Other suggestions on this matter are most welcome.

The proceedings of this conference will be published in a book form, by Plenum Press, as were the three conferences which preceded this one.

The scientific advisory board of this conference is comprised of leaders in the field of Alzheimer's and Parkinson's disease research and clinical care (they are listed on the letterhead). Together, my co-organizers and I are working on a conference program which will highlight the most current topics of interest; one which looks to the future, with a prediction of developments and discoveries of emerging importance. Ample time will be provided for open and productive discussion of new fields and directions.

I am glad to inform you that the response to the First Announcement of the AD/PD 97 is very enthusiastic. So far, a number of key individuals in the field have replied positively and I expect a real success. A number of symposia were suggested already. This meeting promises to bring together many of the leading researchers tackling these disease states. I am taking the liberty of enclosing a copy of a questionnaire soliciting indications of interest in participating in this conference.

Source: https://www.industrydocuments.ucsf.edu/docs/xxbb0000

Please feel free to duplicate and distribute as many copies as necessary to your colleagues. Clearly your support will be most valuable. I also hope that some of your colleagues will plan to attend the conference and participate in it as well, including yourself, of course.

Looking forward to your response to this letter, I remain.

Sincerely yours,

Abraham Fisher, Ph.D.
Conference Coordinator

Source: https://www.industrydocuments.ucsf.edu/docs/xxbb0000